

PATIENT EDUCATION

Video: Lung Cancer Living Room

Watch the latest Lung Cancer Living Room

discussing overcoming resistance to targeted therapy. Dr. Collin Blakely, UCSF, shared insights into how genetic mutations fuel lung

cancer growth, the challenge of acquired resistance to targeted therapies, and promising research toward overcoming resistance. Teri Kennedy, a lung cancer survivor and advocate active in bringing together EGFR-resistor patients, shared her experiences from the patient perspective. [Watch the Video](#)



[Watch the Video](#)

ADVOCACY

ALCF Recognizes Groundbreaking Researcher

Each year Bonnie J. Addario presents a very prestigious award at the International Lung Cancer Congress (ILCC).

Vassiliki A. Papadimitrakopoulou, M.D. will be the

recipient of the 2018 Addario Lectureship Award for her

groundbreaking clinical research leading to international advances in

immunotherapy targeted lung cancer treatments. To register for the

conference for only \$50, enter code ILC18BAF. [SCROLL DOWN to](#)

[view flyer with more information](#)




RESEARCH

More Treatment or Surgery Alone?

Liquid Biopsy Study Opens for Enrollment

'More treatment or just surgery?' is a question many physicians face when determining treatment for lung cancer patients. A new clinical study launched by the Addario Lung Cancer Medical Institute (ALCMI), Drs.

Ramaswamy Govindan and Daniel Morgensztern, and Inivata hopes to help answer that question in patients with early non-small cell lung cancer (NSCLC). [SCROLL DOWN to read the full article](#)



PARTNERSHIPS

Newly Formed Partnership with Precision Medicine Alliance Advances Patient Care

As the one-size-fits-all approach to lung cancer treatment is gradually replaced by personalized medicine, ALCF is taking an active role in bringing the patient's voice into the conversation. ALCF

entered into a strategic partnership with [Precision Medicine Alliance, LLC \(PMA\)](#), a joint venture between Dignity Health and Catholic Health Initiatives. **SCROLL DOWN to read the full article**



FUNDRAISING

Fundraise with ALCF!

Join a 5K run/walk event and help increase patient survival.

[Sep 16 - HOLLYWOOD, FL](#) [Sep 29 - SAN FRANCISCO,](#)

[CA](#)

[Oct 14 - PHILADELPHIA, PA](#)



ALCF NEWS

New Director of Science and Research

ALCF is delighted to welcome Dr. Amy Moore as Director of Science and Research. Dr. Moore, a trained cancer research scientist with decades of experience in the nonprofit sector, looks forward to advancing ALCF's research efforts. [Click here to read more](#)



lungcancerfoundation.org

[Donate](#)



RESEARCH

Patients: Liquid Biopsy Study Opens for Enrollment

More treatment or just surgery? This a question many physicians face when determining treatment for lung cancer patients. A new clinical study launched by the Addario Lung Cancer Medical Institute (ALCMI), Drs. Ramaswamy Govindan and Daniel Morgensztern, and Inivata hopes to help answer that question in patients with early non-small cell lung cancer (NSCLC).

The study will use Inivata's InVision liquid biopsy platform to locate and test circulating tumor DNA (ctDNA) in patients' blood samples. Researchers hope the study will identify which patients with early non-small cell lung cancer (NSCLC) have been successfully treated with surgery alone and which patients require more treatment.

"ALCF is proud of our role in bringing together these distinguished individuals and institutions for this important project," said David LeDuc, ALCF Executive Director. "As a patient focused advocacy organization, one of our main goals is to help advance treatment options, technologies and



Ramaswamy Govindan, MD



Daniel Morgensztern, MD

diagnostic tools that directly benefit patients. This collaboration is a great example of how we utilize our network to find partners with a common mission and to drive the change needed to make lung cancer a chronically-managed disease."

How it works

Until now, an invasive surgical biopsy was the only way to learn about a tumor's genetic markers and proteins. In some patients with lung cancer, doctors can't perform tissue biopsies because of the tumor location or the risk of serious side effects, such as a collapsed lung. Also, because tumor cells can be different even within small tumors, surgical biopsies must remove enough tissue for thorough testing, and the pathologist examining the tumor tissue need to be able to test cells from different parts of the tumor. In addition, tumor cells change when patients go through treatment, requiring repeated surgical biopsies that many patients cannot tolerate.

With liquid biopsies, patients only undergo a simple blood test. When cancer is present, circulating tumor DNA (ctDNA), genetic material shed from tumors, enters the bloodstream. Inivata's InVision platform detects and identifies this tumor material.

"We will test patients with early-stage NSCLC before surgery and up to five years after surgery," said Ramaswamy Govindan, MD, an oncologist and professor of medicine at Washington University School of Medicine in St. Louis. "We also hope to study the utility of ctDNA testing for detecting early signs of recurrence."

Why it matters

"Studies like this are imperative for lung cancer management as they allow us to have much greater access to important genomic information that will drive more informed treatment decisions," said Professor Clive Morris, chief medical officer of Inivata.

Tony Addario, Chair and CEO of ALCMI added, "Providing the ability to identify if and when a change to a patient's current treatment regimen might be appropriate holds great promise for improving treatment for lung cancer patients. The field of liquid biopsy, and ctDNA analysis specifically, is undergoing rapid development, and we're only now beginning to see the potential of what we may be able to achieve."

How you can help

"Patients are our most important partners in clinical research," said Bonnie J. Addario, founder and CEO of the Addario Lung Cancer Foundation (ALCF). "We need more patients to participate in studies like this one to advance our understanding of lung cancer so that we can develop better treatments. Patients are key to improving treatment options, and ultimately finding a cure for lung cancer."

The LIBERTI (Liquid Biopsy in Early Stage NSCLC Resected Lung Tumor Investigation) study will recruit up to 500 patients from eight ALCMI member institutions in the U.S. The study is currently open to enrollment at Washington University in St. Louis and Northside Hospital in Atlanta. ALCMI has plans to add more sites to the trial. For more information, please contact Nurse Alicia at 203-768-9733.

PARTNERSHIPS

Newly Formed Partnership with Precision Medicine

Alliance Advances Patient Care

As the one-size-fits-all approach to lung cancer treatment is gradually replaced by personalized medicine, ALCF is taking an active role to bring the patient's voice into the conversation. As part of that initiative, ALCF has entered into a strategic partnership with the **Precision Medicine Alliance (PMA)**, LLC, a joint venture between **Dignity Health** and **Catholic Health Initiatives**.

The PMA represents 139 hospitals across 28 states and is committed to improving patient care by building genomics-informed solutions and services for the providers, staff, and patients. In creating a central hub of patient clinical and genetic information, the PMA both supports health care providers and provides patient-specific opportunities that complement the work of its physicians.

The PMA's initial program, the precision oncology program, creates unique opportunities for its doctors and other clinicians by working with various industry partners and nonprofits that share the same goal of improving patient care through precision medicine. The partnership between ALCF and the PMA benefits patients by joining ALCF's valuable patient educational resources, research and services with the PMA's expansive network and outreach.

"It is critically important in all clinical strategies to keep the patient as the focus," said Damon Hostin, administrative director & CEO of the Precision Medicine Alliance. "Partnering with Bonnie and team assures our work is always going in the right direction; ALCF continues to show the way."

ALCF and PMA are exploring additional partnership opportunities—namely through the Addario Lung Cancer Medical Institute (ALCMI) and Dignity Health and Catholic Health Initiatives' research enterprises.



**19th Annual
International
Lung Cancer
CONGRESS®**

**Exclusive Invitation for Friends of
the Bonnie J. Addario Lung Cancer
Foundation!**

Use code **ILC18BAF** at gotoper.com/go/ILC18REG
for to register for only \$50!

The **19th Annual International Lung Cancer Congress®** will provide current, practical information on the management of lung cancer, as well as a look at the novel agents and strategies with the potential to shape the future of lung cancer therapy. Leading international and national experts will provide perspectives on how to incorporate the latest data on targeted agents, immunotherapy, surgery, and radiation oncology in the clinic. Cutting-edge lectures, panel discussions, multidisciplinary tumor boards, and interactive question-and-answer sessions will provide a unique opportunity for participants to engage with faculty as they share their perspectives and personal experiences on the clinical challenges and ongoing controversies in lung cancer management.

July 26-28, 2018
Hyatt Regency Huntington Beach
21500 Pacific Coast Highway,
Huntington Beach, CA 92648

PROGRAM DIRECTORS

David R. Gandara, MD
Professor of Medicine
Division of Hematology/Oncology
Director, Thoracic Oncology
Program
Senior Advisor to the Director
UC Davis Comprehensive Cancer
Center
Sacramento, CA

Roy S. Herbst, MD, PhD
Ensign Professor of Medicine
(Medical Oncology)
Professor of Pharmacology
Chief of Medical Oncology
Associate Director for
Translational Research
Yale Cancer Center
Yale School of Medicine
New Haven, CT

[Click here for more information](#)

